Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
February 15, 2024
RegMed Investors (RMi) Research Note: Prime Medicine (PRME) Prices 19million share offering at $6.25
February 13, 2024
RegMed (RMI) Research Note: CRISPR Therapeutics (CRSP) Registered Direct Offering (RDO) $280 M offering priced at $71.50
February 5, 2024
RegMed Investors (RMi): Adverum Biotechnologies (ADVM) 106.25 M Share Private Placement priced at $1.20
January 18, 2024
RegMed Investors (RMi) Research Note: Mesoblast (MESO) FDA Grants Mesoblast Rare Pediatric Disease Designation for Revascor® (Rexlemestrocel-L)
January 8, 2024
RegMed Investors (RMi) Research Note: Solid Biosciences (SLDB) Announces $109 Million Private Placement
January 5, 2024
RegMed Investors (RMi) Research Note: Voyager Therapeutics (VYGR) prices 7.77 M share public offering at $9.00 per share
January 2, 2024
RegMed Investors (RMi) Research Note: Voyager Therapeutics (VYGR) juices after Novartis (NVS) licensing deal
December 20, 2023
RegMed Investors (RMi): bluebird bio (BLUE) prices $1.50 for 83 m stock offering
November 29, 2023
RegMed Investors (RMi) Research Financing Note: Verve Therapeutics (VERV) has priced its public offering of 12.5 M shares at $10.00
November 16, 2023
RegMed Investors (RMi) Research Note: Homology Medicines (FIXX) enters into merger agreement and financing with Q32 Bio Inc. in an all-stock transaction
October 19, 2023
RegMed Investors (RMi) Research Note: Beam Therapeutics (BEAM) reduces headcount
October 18, 2023
RegMed Investors (RMi) Research Note: Ultragenyx Pharmaceutical (RARE) has priced its public offering at $30.00 per share of 8,33 M stock
August 18, 2023
RegMed Investors (RMi) Research Note: Q2/23 net losses earnings, cash positions and runway outcomes
July 31, 2023
RegMed Investors (RMi) Research Note: Q2/2023 earnings reporting date announcements
July 3, 2023
Happy 4th of July and week
June 21, 2023
RegMed Investors (RMi) Research Note: Editas Medicine (EDIT) prices a $125 M offering of 12.5 M shares at $10.00
June 21, 2023
RegMed Investors (RMi) Research Note: UniQure NV (QURE -$8.08 or -41.72% to $11.33) crashed
May 27, 2023
RegMed Investors (RMi) Research Note: Q1/23 earnings reporting dates, net losses, cash positions and runway outcomes
May 15, 2023
UniQure NV (QURE) to sell royalty interest in blood disorder therapy for up to $400 M
April 10, 2023
RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting
March 17, 2023
RegMed Investors (RMi) Research Note: Silicon Valley Bank Group (SIVB) files for bankruptcy
March 13, 2023
RegMed investors (RMi) Research Note: the aftermarket of catching a falling knife without a cut or slash
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2025 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.